Drug Discovery World article quoting Max Baumann, Partner at Treehill
???? ???????????? “???????????????????? ????????????????????????????????????” ???????? ???????????????? – ???????????? ????????’???? ???????????????????????????????????? ???????????????????????? ???????????????????????????? ????
An extraordinary 75% of US scientists are considering leaving America due to policy uncertainty and NIH funding cuts. European universities are responding with new grant programs, creating an unprecedented “brain drain” from the US to Europe.
As we told DDW: “???????????????????????????? ???????????????????????????????????????? ???????????????????????????? ???????????????????????? ????????????????????????????????????, ???????????????????????????????? ???????????????????????????????????????????? ???????????? ???????????????????????????? ???????????????????????????????????? ????????????????????????????????.”
???????????? ???????????????????????? ???????? ???????????????????????????? ????????????????????????????:
✔️ Big pharma rushing to invest in US operations ($50B from Roche, $55B from J&J) to avoid tariffs
✔️ European biotech saw 25.4% funding decline while APAC grew 55.3%
✔️ Switzerland still attracted CHF 2.5 billion despite global headwinds
✔️ EU launching €500M “super grants” package to retain and attract talent
But here’s what most aren’t seeing: this disruption creates unprecedented restructuring opportunities for companies positioned to navigate the capital geography shift.
???????????? ???????????????????????????????? ????????????’???? ???????????????????????????? ???????????????????????? ???????????? ???????????????? ???????????? ???????????????? – it’s how companies will position themselves to capture value from this massive realignment of global biotech infrastructure.
❓ How is your organization adapting to this new geopolitical reality? Are you seeing opportunities emerge from the constraints?
???? What strategic moves are you considering beyond just “waiting for stability”?
???? Treehill Partners – helping biopharma companies navigate complex market transitions and optimize strategies for both regulatory success and commercial value creation across changing global landscapes.
Read the full article on:
https://www.ddw-online.com/can-europe-take-the-lead-on-biotech-35716-202507/